Abstract
BackgroundIntravenous belimumab (BEL) 10 mg/kg is approved in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE), on standard SLE therapy (SoC). A Phase III, double-blind (DB), study of subcutaneous...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
